ÀλêÈµÈ FAK ´Ü¹éÁúÀº OSCC ¼¼Æ÷¿¡¼ ³ô°Ô ¹ßÇöµÊ. p-FAK/GNP ó¸®µÈ SCC25 ¼¼Æ÷¿¡ ´ëÇÑ Ç÷Àå Ȱ¼ºÈ ¹èÁö ó¸®ÀÇ È¿°ú´Â Á÷Á¢ NCP 󸮺¸´Ù ¾àÇÔ. NCP ó¸® Áß ÀüÀÚ Á¢Áö ¸Þ½¬ ¹èÄ¡ Hindersp-FAK/GNP+NCP ¸Å°³ SCC25 ¼¼Æ÷ »ç¸ê µÊ. »ýÁã ÀÌÁ¾ÀÌ½Ä ¸ðµ¨¿¡¼ NCP¿Í p-FAK/GNPÀÇ º´¿ë Ä¡·áÀÇ ½Ã³ÊÁö Ç×Á¾¾ç È¿°ú ÀÖÀ½. NCP¿Í ÇÔ²² pFAK/GNP·Î ó¸®ÇÑ ¸¶¿ì½º¿¡¼ ºÐ¸®ÇÑ Á¶Á÷Àº Á¾¾çÀÌ ¾Æ´Ï¾úÀ½.
Anti-Cancer Activity of the
Combinational Treatment of Noozone Cold Plasma with p-FAK Antibody-Conjugated Gold Nanopar